| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI149804 | Discovery of Treponema pallidum antigens for development of a sensitive and specific diagnostic test for syphilis | 000 | 2 | NIH | 11/15/2023 | $0 |
| | 2024 | 2021 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI145607 | Scanning the Cryptosporidium proteome for vaccine antigens | 000 | 2 | NIH | 2/12/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | IMMPORT THERAPEUTICS, INC. | 1 Technology Dr Ste E309 | Irvine | CA | 92618-2343 | ORANGE | USA | R43IP001168 | Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus | 03 | 1 | CDC | 3/17/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $296,034 ) |
| | 2022 | 2022 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI157561 | Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine candidates against Neisseria meningitidis | 000 | 2 | NIH | 4/11/2022 | $296,034 |
| | 2022 | 2021 | Immport Therapeutics, Inc. | 1 Technology Dr Ste E309 | Irvine | CA | 92618-2343 | ORANGE | USA | R43IP001168 | Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus | 02 | 1 | CDC | 9/29/2022 | $0 |
| | 2022 | 2021 | Immport Therapeutics, Inc. | 1 Technology Dr Ste E309 | Irvine | CA | 92618-2343 | ORANGE | USA | R43IP001168 | Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus | 01 | 1 | CDC | 12/9/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,142,999 ) |
| | 2021 | 2021 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI157561 | Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine candidates against Neisseria meningitidis | 000 | 1 | NIH | 5/12/2021 | $300,000 |
| | 2021 | 2021 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI145607 | Scanning the Cryptosporidium proteome for vaccine antigens | 000 | 2 | NIH | 3/18/2021 | $299,999 |
| | 2021 | 2021 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI149804 | Discovery of Treponema pallidum antigens for development of a sensitive and specific diagnostic test for syphilis | 000 | 2 | NIH | 12/23/2020 | $300,000 |
| | 2021 | 2021 | Immport Therapeutics, Inc. | 1 Technology Dr Ste E309 | Irvine | CA | 92618-2343 | ORANGE | USA | R43IP001168 | Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus | 00 | 1 | CDC | 8/30/2021 | $243,000 |
| | 2021 | 2019 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI136197 | Discovery of Yellow Fever Virus-Specific Epitopes for Development of an Accurate Serodiagnostic Assay | 000 | 2 | NIH | 6/30/2021 | $0 |
| | 2021 | 2018 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI136196 | Pan-HIV Incidence Assay Development | 000 | 1 | NIH | 2/6/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $600,000 ) |
| | 2020 | 2020 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI145607 | Scanning the Cryptosporidium proteome for vaccine antigens | 000 | 1 | NIH | 3/27/2020 | $300,000 |
| | 2020 | 2020 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI149804 | Discovery of Treponema pallidum antigens for development of a sensitive and specific diagnostic test for syphilis | 000 | 1 | NIH | 12/30/2019 | $300,000 |
|
| Issue Date FY: 2019 ( Subtotal = $295,679 ) |
| | 2019 | 2019 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI136197 | Discovery of Yellow Fever Virus-Specific Epitopes for Development of an Accurate Serodiagnostic Assay | 000 | 2 | NIH | 12/19/2018 | $295,679 |
| | 2019 | 2018 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI138827 | Protective biomarkers for the development of novel serotype-independent protein-based vaccine candidates against pneumococcus | 000 | 1 | NIH | 7/26/2019 | $0 |
| | 2019 | 2017 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI132078 | Specific Detection of Antibodies to Emerging and Established Arboviruses Including Zika Virus | 000 | 1 | NIH | 5/29/2019 | $0 |
| | 2019 | 2016 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI124911 | A NOVEL IMMUNO-PROTEOMIC APPROACH TO A GENITAL HERPES VACCINE | 000 | 1 | NIH | 3/21/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $750,123 ) |
| | 2018 | 2018 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-3832 | ORANGE | USA | R43AI138827 | Protective biomarkers for the development of novel serotype-independent protein-based vaccine candidates against pneumococcus | 000 | 1 | NIH | 3/21/2018 | $224,852 |
| | 2018 | 2018 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-3832 | ORANGE | USA | R43AI136197 | Discovery of Yellow Fever Virus-Specific Epitopes for Development of an Accurate Serodiagnostic Assay | 000 | 1 | NIH | 1/16/2018 | $299,564 |
| | 2018 | 2018 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-3832 | ORANGE | USA | R43AI136196 | Pan-HIV Incidence Assay Development | 000 | 1 | NIH | 8/16/2018 | $225,707 |
| | 2018 | 2015 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-3832 | ORANGE | USA | R43DE025440 | Point of Care Detection of Oral Pathogens | 000 | 1 | NIH | 1/30/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $224,958 ) |
| | 2017 | 2017 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-3832 | ORANGE | USA | R43AI132078 | Specific Detection of Antibodies to Emerging and Established Arboviruses Including Zika Virus | 000 | 1 | NIH | 2/3/2017 | $224,958 |
| | 2017 | 2014 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-3832 | ORANGE | USA | R43DE025165 | Development of a Pan-HIV Proteomic Chip | 000 | 1 | NIH | 2/6/2017 | $0 |
| | 2017 | 2014 | IMMPORT THERAPEUTICS, INC. | 1 TECHNOLOGY DR STE E309 | IRVINE | CA | 92618-3832 | ORANGE | USA | R44AI066791 | Protective biomarkers for the development of vaccines against malaria | 000 | 5 | NIH | 1/10/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $224,911 ) |
| | 2016 | 2016 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI124911 | A NOVEL IMMUNO-PROTEOMIC APPROACH TO A GENITAL HERPES VACCINE | 000 | 1 | NIH | 7/15/2016 | $224,911 |
| | 2016 | 2014 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618 | ORANGE | USA | R43DE025165 | Development of a Pan-HIV Proteomic Chip | 000 | 1 | NIH | 4/7/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $225,000 ) |
| | 2015 | 2015 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618-2343 | ORANGE | USA | R43DE025440 | Point of Care Detection of Oral Pathogens | 000 | 1 | NIH | 8/19/2015 | $225,000 |
|
| Issue Date FY: 2014 ( Subtotal = $1,003,631 ) |
| | 2014 | 2014 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618-2343 | ORANGE | USA | R44AI066791 | Protective biomarkers for the development of vaccines against malaria | 000 | 5 | NIH | 7/21/2014 | $778,631 |
| | 2014 | 2014 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618-2343 | ORANGE | USA | R43DE025165 | Development of a Pan-HIV Proteomic Chip | 000 | 1 | NIH | 9/16/2014 | $225,000 |
|
| Issue Date FY: 2013 ( Subtotal = $1,080,873 ) |
| | 2013 | 2013 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI102288 | INTEGRATED MICROFLUIDIC PLATFORM FOR POINT-OF-CARE SERODIAGNOSTICS | 000 | 2 | NIH | 7/16/2013 | $300,000 |
| | 2013 | 2013 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618-2343 | ORANGE | USA | R44AI066791 | Protective biomarkers for the development of vaccines against malaria | 000 | 4 | NIH | 7/19/2013 | $780,873 |
|
| Issue Date FY: 2012 ( Subtotal = $1,081,909 ) |
| | 2012 | 2012 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618-2343 | ORANGE | USA | R43AI102288 | INTEGRATED MICROFLUIDIC PLATFORM FOR POINT-OF-CARE SERODIAGNOSTICS | 000 | 1 | NIH | 7/19/2012 | $300,000 |
| | 2012 | 2012 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618-2343 | ORANGE | USA | R44AI066791 | Protective biomarkers for the development of vaccines against malaria | 000 | 3 | NIH | 8/3/2012 | $781,909 |
|
| Issue Date FY: 2011 ( Subtotal = $0 ) |
| | 2011 | 2010 | IMMPORT THERAPEUTICS INC | 1 TECHNOLOGY DRIVE | IRVINE | CA | 92618 | ORANGE | USA | R44AI058365 | SERIODIAGNOSTIC ARRAYS FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES | 000 | 5 | NIH | 8/3/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $1,865,480 ) (Continued on the next page) |
|
